Product Details

Hydromorph Contin

Hydromorphone HCl
24 mg
CR Capsule


DIN/PIN/NPN

02125382

Manufacturer

Purdue Pharma

Formulary Listing Date

1998-12-31  

Unit Price

4.1810

Amount MOH Pays

4.1810

Coverage Status

Off-Formulary Interchangeable Exceptional Access Program Product

ODB Formulary Therapeutic Classification

Therapeutic Note

Analgesics, Opiate Agonists (28:08:08): Narcotic analgesics can produce dependence and may be abused. Physical dependence, psychological dependence and tolerance may develop. Prescribers are cautioned about ordering these drugs for patients with a history of either emotional disturbances or drug abuse, including alcohol.

ATC Code

N02AA03

Interchangeable Products

NO  

LU Clinical Criteria

NO  

EAP Criteria

Therapeutic Class Reimbursement Criteria
High Dose Opioids – Telephone Request Service (TRS) Drugs

Effective January 31, 2017, meperidine 50mg tabs and the higher strengths of long-acting opioids including: morphine SR 200mg tabs; hydromorphone CR 24mg and 30 mg caps and fentanyl 75mcg/hr and 100mcg/hr patches were delisted from the ODB Formulary.

Access to the higher strengths of long-acting opioids is currently maintained for patients requiring palliative care through the ODB program’s:

  1. Palliative Care Facilitated Access (PCFA) mechanism, for prescribers (physicians or nurse practitioners) who are registered PCFA prescribers with their professional associations; AND
  2. Exceptional Access Program (EAP) Telephone Request Service (TRS) for physicians who are not PCFA prescribers, according to specific criteria.
    i) Use of the high-strength opioid must be for a patient considered to have a progressive life-limiting illness requiring palliative care.
    ii) The use of the high-strength opioid can be for pain or for symptom management.
    iii) Prescriber must have a consult from a PCFA-registered prescriber with OMA; CPSO of the PCFA-registered prescriber or NPAO or RNAO; license numbers must be provided.

Standard Approval Duration: 12 months

Renewals are considered with same criteria as above. A new consult from a PCFA-registered prescriber must be provided for each renewal.

Product Monograph

View Monograph